Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
October 28 2024 - 8:30AM
UK Regulatory
Michael McDonnell, Executive Vice President and Chief Financial
Officer to Retire in February 2025
Robin Kramer, Chief Accounting Officer, to Succeed
Him
CAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) --
Biogen Inc. (Nasdaq: BIIB) today announced that Michael McDonnell,
Biogen’s Executive Vice President and Chief Financial Officer,
plans to retire from the company on February 28, 2025. Upon Mr.
McDonnell’s retirement, Robin Kramer, currently Chief Accounting
Officer at Biogen, will assume the role of Chief Financial Officer
(CFO). In the coming weeks and months, Mr. McDonnell will work
closely with Ms. Kramer to ensure a smooth transition.
Mr. McDonnell, who has served in his current role since August
2020, has been instrumental to repositioning Biogen towards the
goal of returning to sustainable growth. He notably led a program
to re-align the company’s cost structure to its revenue base and to
redeploy capital in areas of potential growth. As part of these
efforts, Mr. McDonnell played a pivotal role in recent strategic
acquisitions of late-stage assets and in creating a culture of
financial discipline and continuous improvement across the
company.
“On behalf of the Board of Directors and our entire leadership
team, I would like to extend our gratitude to Mike for his years of
dedication to Biogen. In the two years we have worked
together, Mike has demonstrated strong leadership during our Fit
for Growth program, and he has been an important and valued counsel
for me and our team,” said Christopher A. Viehbacher, Biogen
President and Chief Executive Officer.
“Mike leads a strong team, and I am pleased to be able to
announce that Robin Kramer will succeed Mike as Executive Vice
President and CFO when Mike retires early next year. Her deep
understanding of our business, coupled with her breadth of
knowledge and leadership experience give me great confidence in her
as our next CFO,” Viehbacher continued. “Robin will join the
Executive Committee and work with our leadership team to build
upon Biogen’s transformation and further advance our strategic
vision.”
Ms. Kramer joined Biogen in 2018 and has served as Senior Vice
President and Chief Accounting Officer since 2020. In this
capacity, she has overseen key finance functions including
Treasury. She is also responsible for global procurement and
Biogen's Global Business Services operations. She brings a strong
track record of corporate financial and accounting experience
across different industries, including biotechnology, and will
continue to be a key contributor to the advancement of Biogen’s
sustained performance. She has partnered with Mr. McDonnell and the
rest of the leadership team on the company’s M&A strategy and
other strategic growth initiatives. Ms. Kramer works closely with
the Board of Directors and the Audit Committee.
“I am honored to assume the role of CFO as Biogen continues to
execute on its strategic transformation for the benefit of our
patients, partners, employees and shareholders,” said Ms. Kramer.
“Mike has been a wonderful mentor to me the last few years, and I
look forward to working with Chris, the Executive Committee and the
Board as we continue to advance and deliver on the strategic and
financial objectives, which we believe are core to Biogen’s next
chapter of biotech leadership and our ability to create attractive
returns for our shareholders.”
Before joining Biogen, Ms. Kramer held senior finance roles at
Hertz Global Holdings, Inc., Fisher Scientific International, Inc.
and The Gillette Company, and was an audit partner at Deloitte
& Touche LLP, Ernst & Young LLP and Arthur Andersen LLP.
Ms. Kramer currently serves as Chair of the Board of Directors and
Audit Committee of Armata Pharmaceuticals and serves on the Board
of Directors and Finance Committee of the Center for Women and
Enterprise. She holds a B.S.B.A. in Accounting from Salem State
University and is a licensed CPA in the Commonwealth of
Massachusetts.
“I am deeply grateful for my time at Biogen and for the
company’s unwavering commitment to patients, which has profoundly
impacted me. It has truly been a privilege serving as Biogen's
Chief Financial Officer," said Mike McDonnell. "While I look
forward to retirement and the opportunity to spend more time with
my family, who have supported me throughout my career, I will miss
working alongside my exceptional colleagues. I'm especially
grateful to Robin Kramer for her partnership and congratulate her
on her appointment as Biogen’s next CFO; I am confident she will
excel in this role.”
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that
pioneers innovative science to deliver new medicines to transform
patients’ lives and to create value for shareholders and our
communities. We apply deep understanding of human biology and
leverage different modalities to advance first-in-class treatments
or therapies that deliver superior outcomes. Our approach is to
take bold risks, balanced with return on investment to deliver
long-term growth.
We routinely post information that may be important to investors
on our website at www.biogen.com. Follow us on social
media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including
regarding the potential of Biogen's commercial business and
pipeline programs; the anticipated benefits and potential of
investments, optimization of our cost structure, Biogen’s future
strategic and financial results. These statements may be identified
by words such as "aim," "anticipate," "believe," "could,"
"estimate," "expect," "forecast," "intend," "may," "plan,"
"possible," "potential," "will," "would" and other words and terms
of similar meaning. Drug development and commercialization involve
a high degree of risk, and only a small number of research and
development programs result in commercialization of a product.
Results in early-stage clinical studies may not be indicative of
full results or results from later stage or larger scale clinical
studies and do not ensure regulatory approval. You should not place
undue reliance on these statements.
These statements involve risks and uncertainties that could cause
actual results to differ materially from those reflected in such
statements, including without limitation unexpected concerns that
may arise from additional data, analysis or results obtained during
clinical studies; the occurrence of adverse safety events; risks of
unexpected costs or delays; the risk of other unexpected hurdles;
regulatory submissions may take longer or be more difficult to
complete than expected; regulatory authorities may require
additional information or further studies, or may fail or refuse to
approve or may delay approval of Biogen's drug candidates; actual
timing and content of submissions to and decisions made by the
regulatory authorities regarding our products or product
candidates; uncertainty of success in the development and potential
commercialization of the medicine; failure to protect and enforce
Biogen's data, intellectual property and other proprietary rights
and uncertainties relating to intellectual property claims and
challenges; product liability claims; and third party collaboration
risks, results of operations and financial condition. The foregoing
sets forth many, but not all, of the factors that could cause
actual results to differ from Biogen's expectations in any
forward-looking statement. Investors should consider this
cautionary statement as well as the risk factors identified in
Biogen's most recent annual or quarterly report and in other
reports Biogen has filed with the U.S. Securities and Exchange
Commission. These statements speak only as of the date of this news
release. Biogen does not undertake any obligation to publicly
update any forward-looking statements.
MEDIA CONTACT:
Biogen
Jack Cox
+ 1 781 464 3260
public.affairs@biogen.com
|
INVESTOR CONTACT:
Biogen
Stephen Amato
+1 781 464 2442
IR@biogen.com |
Biogen (BIT:1BIIB)
Historical Stock Chart
From Oct 2024 to Nov 2024
Biogen (BIT:1BIIB)
Historical Stock Chart
From Nov 2023 to Nov 2024